Untitled - Media Med Publicis

PROGRESE ÎN CARDIOLOGIE / 29
Survey ACS). Eur. Heart J. 2002; 23: 1190-1201.
7 Zipes D.P., Libby P., Bonow R.O., Braunwald E. (eds.). Braunwald’s Heart Disease. A
Textbook of Cardiovascular Medicine. Elsevier Saunders, 2005.
8 Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J.
Med. 2005; 352: 1685-95.
9 Pasceri V., Willerson J.T., Yeh E.T. Direct proinflammatory effect of C-reactive protein
on human endothelial cells. Circulation 2000; 102: 2165-8.
10 Maier W., Altwegg L.A., Corti R., et al. Inflammatory markers at the site of ruptured
plaque in acute myocardial infarction locally increased interleukin-6 and serum amyloid
A but decreased C-reactive protein. Circulation 2005; 111: 1355-1361.
11 Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease
detection and prevention. Circulation 2003; 107: 363-9.
12 Ridker P.M., Hennekens C.H., Buring J.E., et al. C-reactive protein and other markers
of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med.
2000; 342: 836-43.
13 Ridker P.M., Rifai N., Rose L., et al. Comparison of C-reactive protein and low-density
lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J.
Med. 2002; 347: 1557-65.
14 Ridker P.M., Buring J.E., Cook N.R., et al. C-reactive protein, the metabolic syndrome,
and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy
American women. Circulation 2003; 107: 391-97.
15 Blake G.J., Rifai N., Buring J.E., et al. Blood pressure, C-reactive protein, and risk of
future cardiovascular events. Circulation 2003; 108: 2993-9.
16 Ridker P.M., Wilson P.W., Grundy S.M. Should C-reactive protein be added to metabolic
syndrome and to assessment of global cardiovascular risk Circulation 2004; 109: 2818-
25.
17 Smith S.C. Jr., Anderson J.L., Cannon R.O., et al. CDC/AHA Workshop on markers
of inflammation and cardiovascular disease: application to clinical and public health
practice: report from the clinical practice discussion group. Circulation 2004; 110: 550-3.
18 Sabatine M.S., Braunwald E. Another look at the age-old question which came first, the
elevated C-reactive protein or the atherothrombosis J. Am. Coll. Cardiol. 2005; 45:
244-5.
19 Ridker P.M. JUPITER Study Group. Rosuvastatin in the primary prevention of
cardiovascular disease among patients with low levels of low-density lipoprotein
cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the
JUPITER trial. Circulation 2003; 108: 2292-7.
20 Frosst P., Blom H.J., Milos R., et al. A candidate genetic risk factor for vascular disease:
a common mutation in methylenetetrahydrofoloate reductase. Nat. Genet. 1995; 10:
1113.
21 Wald D.S., Law M., Morris J.K. Homocysteine and cardiovascular disease: evidence on
causality from a meta-analysis. BMJ 2002; 325: 1202-6.
22 Hoogeven E.K., Kostense P.J., Jacobs C., et al. Hyperhomocysteinemia increases risk
of death, especially in type 2 diabetes. 5-year follow-up of the Hoorn study. Circulation
2000; 101; 1506-11.
23 Nygard O., Nordrehaug J.E., Refsum H., et al. Plasma homocysteine levels and mortality
in patients with coronary artery disease. N. Engl. J. Med. 1997; 337; 230-36.
24 Zylberstein D.E., Bengtsson C., Bjorkelund C., et al. Serum homocysteine in relation